Twist Bioscience, which manufactures synthetic genes and other DNA-based products, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering.
The San Francisco, CA-based company was founded in 2013 and booked $20 million in revenue for the 12 months ended June 30, 2018. It plans to list on the Nasdaq under the symbol TWST. Twist Bioscience filed confidentially on February 8, 2018. J.P. Morgan and Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.
